NPC1L1 and colorectal carcinoma: Most of the LDL-lowering drug-targets examined were not associated with CRC or its subsites, except for genetically-proxied NPC1L1 inhibition which was associated with higher proximal colon cancer risk (OR = 2.29; 1.14-4.58 per SD decrease in LDL-C), but this association was no longer statistically-significant when independent SNPs were used (Fig. 3) and was not supported by our colocalization results (Additional file 2: Table S12).